Vera Therapeutics is trading 4% up at $43.16 as momentum continues from the recent FDA accelerated approval of its IgA nephropathy drug, atacicept (Trutakna).

  • The stock is outperforming the broader biotech sector as investors focus on the company's de-risked regulatory pathway following the July 7 approval.
  • Multiple analysts have reiterated bullish ratings, highlighting significant upside potential tied to upcoming Phase 3 eGFR data.